insulin resistance glp-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Non-insulin injectable antidiabetic drugs -

Ending obesity coverage for GLP-1 obesity drugs could improve the states finances but might also result in health inequities and less comprehensive coverage, the states health and human services agency acknowledged in its September budget request

6 Victoza (Liraglutide 18 mg) subcutaneous injection, Rx only, has not been approved by the FDA as safe and effective to treat obesity and overweight

Mounjaro (tirzepatide): Has a half-life of about 5 days, meaning it could take 4-6 weeks to be eliminated

Low levels may develop because of a low salt diet, dehydration, or adrenal exhaustion

Its linked to higher homocysteine levels , a risk factor for heart disease, neural tube defects, and pregnancy complications [4]